Delivery Order SPE2DR25D2104-SPE2DR26F3QJS
- Not listed
- The Defense Logistics Agency awarded a $11,335.78 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Linzess 290 microgram capsules in quantities of 30 units. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement with a completion date of August 19, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $1,711.90 delivery order to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of Linzess 145 microgram capsules (30-count units). This firm fixed-price, competitively awarded contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The pharmaceutical product will be delivered to the company's corporate...
- The Defense Logistics Agency awarded a $9,813.51 delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Linzess 145 mcg capsules (30-count units). This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The pharmaceutical product will be delivered to AmerisourceBergen's distribution facility in Conshohocken, Pennsylvania, with an ultimate completion date of December 10, 2025. AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a $3,268.45 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Linzess 290 micrograms capsules (30-unit pack) on May 27, 2025, with completion scheduled for May 28, 2025. The contract is unset-aside and competitively awarded, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,423.44 to supply Linzess 72 microgram capsules (30-count units) under a firm fixed price contract. The award, issued on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a non-competitive, non-set-aside delivery order. The product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a $2,355.01 delivery order to AmerisourceBergen Drug Corp for Linzess 145 mcg capsules (30-count units) on December 3, 2025, with an ultimate completion date of December 4, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work is performed at AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,099.01 to AmerisourceBergen Drug Corp for the supply of Linzess 145 mcg capsules (30-count units) on December 8, 2025, with an ultimate completion date of December 9, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a relatively small transaction within...
- The Defense Logistics Agency awarded a $1,014.90 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of Linzess 145 micrograms capsules (30-count units). This non-set-aside contract represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Linzess 290 mcg capsules (30-count units) with a ceiling value of $43,043.86. This firm fixed-price delivery order, with an ultimate completion date of December 3, 2025, was competitively awarded without set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery from its...
- The Defense Logistics Agency awarded a $15,605.50 delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Linzess 145 microgram capsules (30-count units). This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be performed at AmerisourceBergen's...
- SPE2DR25D2104Indefinite Delivery Contract
- SPE2DR25D2104-SPE2DR26F3QJSDelivery Order
The Defense Logistics Agency awarded a $3,336.89 delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Linzess 145 microgram capsules (30-count packaging). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of December 3, 2025. The pharmaceutical product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive global pharmaceutical support vehicle running through December 2026. As a prime pharmaceutical vendor, AmerisourceBergen supplies an extensive portfolio of medications and medical products to support military healthcare programs, the Defense Health Agency, and other federal health systems worldwide. The company's federal procurement profile demonstrates consistent capability to meet government medical supply requirements across multiple therapeutic domains through competitive contracting mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 12/1/25 |